NICE recommends new first in class treatment for Generalised Pustular Psoriasis

The National Institute for Health and Care Excellence (NICE) has today published its decision to recommend Spesolimab (also known by its brand name, Spevigo) as the first-ever targeted treatment for Generalised Pustular Psoriasis (GPP) in England and Wales.

GPP is rare form of psoriasis where pustules appear across large areas of the body. It is a serious condition that requires urgent medical attention.

You can read the full NICE Guidance for Spesolimab in the link here.

Helen McAteer, Chief Executive of the Psoriasis Association, said the recommendation "marks a major step forward in addressing a significant unmet need for people living with GPP in England and Wales."

About Spesolimab

Spesolimab, given as an intravenous infusion, is the first targeted and effective drug specifically developed for managing GPP flares.

It is estimated that just over 1,300 people with this condition in England could be set to benefit from this new treatment.

Get involved in our GPP everyday life survey

If you live in the UK, the Psoriasis Association would like to hear about your experiences of living with GPP.

You are invited to take part in a short anonymous online survey. Participants must be over the age of 18.

Your insights will help to shape vital research and support the GPP community.

The survey can be found here: https://www.surveymonkey.com/r/JRSMWQ6

If you require further information, please contact: research@psoriasis-association.org.uk.